Emcure Pharmaceuticals Ltd (EMCURE) - Net Assets
Based on the latest financial reports, Emcure Pharmaceuticals Ltd (EMCURE) has net assets worth Rs48.84 Billion INR (≈ $528.19 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs93.93 Billion ≈ $1.02 Billion USD) and total liabilities (Rs45.09 Billion ≈ $487.58 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Emcure Pharmaceuticals Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs48.84 Billion |
| % of Total Assets | 52.0% |
| Annual Growth Rate | 29.96% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13.14 |
Emcure Pharmaceuticals Ltd - Net Assets Trend (2022–2025)
This chart illustrates how Emcure Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Emcure Pharmaceuticals Ltd asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Emcure Pharmaceuticals Ltd (2022–2025)
The table below shows the annual net assets of Emcure Pharmaceuticals Ltd from 2022 to 2025. For live valuation and market cap data, see EMCURE market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs46.42 Billion ≈ $501.97 Million |
+48.68% |
| 2024-03-31 | Rs31.22 Billion ≈ $337.61 Million |
+17.82% |
| 2023-03-31 | Rs26.50 Billion ≈ $286.55 Million |
+25.33% |
| 2022-03-31 | Rs21.14 Billion ≈ $228.64 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Emcure Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 95.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs33.13 Billion | 74.51% |
| Common Stock | Rs1.89 Billion | 4.26% |
| Other Components | Rs9.44 Billion | 21.23% |
| Total Equity | Rs44.46 Billion | 100.00% |
Emcure Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Emcure Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TransAlta Corp
TO:TA
|
$3.68 Billion |
|
Benefit Systems SA
WAR:BFT
|
$3.68 Billion |
|
Howard Hughes Holdings Inc.
NYSE:HHH
|
$3.68 Billion |
|
Shengda Mining Co Ltd
SHE:000603
|
$3.68 Billion |
|
Pacific Securities Co Ltd
SHG:601099
|
$3.67 Billion |
|
Wynn Macau Limited
F:8WY
|
$3.67 Billion |
|
St Galler Kantonalbank AG
SW:SGKN
|
$3.67 Billion |
|
Pony AI Inc. American Depositary Shares
NASDAQ:PONY
|
$3.67 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Emcure Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 29,522,830,000 to 44,461,860,000, a change of 14,939,030,000 (50.6%).
- Net income of 6,813,320,000 contributed positively to equity growth.
- New share issuances of 7,792,280,000 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs6.81 Billion | +15.32% |
| Share Issuances | Rs7.79 Billion | +17.53% |
| Other Changes | Rs333.43 Million | +0.75% |
| Total Change | Rs- | 50.60% |
Book Value vs Market Value Analysis
This analysis compares Emcure Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 17.06x to 7.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | Rs105.11 | Rs1793.20 | x |
| 2023-03-31 | Rs132.27 | Rs1793.20 | x |
| 2024-03-31 | Rs156.12 | Rs1793.20 | x |
| 2025-03-31 | Rs237.71 | Rs1793.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Emcure Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.32%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.73%
- • Asset Turnover: 0.95x
- • Equity Multiplier: 1.85x
- Recent ROE (15.32%) is below the historical average (21.70%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 33.32% | 11.48% | 0.95x | 3.05x | Rs4.63 Billion |
| 2023 | 21.27% | 8.97% | 0.89x | 2.67x | Rs2.82 Billion |
| 2024 | 16.87% | 7.57% | 0.84x | 2.64x | Rs2.03 Billion |
| 2025 | 15.32% | 8.73% | 0.95x | 1.85x | Rs2.37 Billion |
Industry Comparison
This section compares Emcure Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $35,979,469,852
- Average return on equity (ROE) among peers: 17.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Emcure Pharmaceuticals Ltd (EMCURE) | Rs48.84 Billion | 33.32% | 0.92x | $3.68 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $1.14 Billion | 5.77% | 1.16x | $27.95 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.01 Billion | 13.28% | 2.64x | $390.72 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $13.86 Billion | -0.01% | 0.47x | $790.23 Million |
| Abbott India Limited (ABBOTINDIA) | $1.88 Billion | 54.31% | 0.66x | $5.84 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $5.93 Billion | 39.42% | 0.60x | $3.92 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $925.81 Million |
| Alkem Laboratories Limited (ALKEM) | $49.85 Billion | 12.66% | 0.54x | $6.93 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.26 Billion | 16.93% | 0.29x | $179.06 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $31.90 Billion | 25.98% | 0.88x | $1.63 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $245.74 Billion | 10.78% | 0.38x | $8.64 Billion |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure X… Read more